Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.50 |
| ▸ | PPARA | Q07869 | 20/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312588 | 0.94 | PPARG (0.56) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5225224 | 0.88 | PPARG (0.56) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5227944 | 0.87 | PPARG (0.49) | PPARGPPARACYP2C9KCNH2CYP3A4 | |
| SCHEMBL5226840 | 0.87 | PPARA (0.51) | PPARGPPARA | |
| SCHEMBL5229653 | 0.86 | PPARG (0.52) | PPARGPPARACYP2C9KCNH2CYP3A4 | |
| SCHEMBL5226480 | 0.85 | PPARG (0.57) | PPARGPPARACYP2C9KCNH2CYP3A4 | |
| SCHEMBL5229702 | 0.82 | PPARG (0.51) | PPARGPPARACYP2C9KCNH2CYP3A4 | |
| SCHEMBL5228557 | 0.82 | PPARG (0.64) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5227831 | 0.81 | PPARG (0.52) | PPARGPPARACYP2C9KCNH2CYP3A4 | |
| SCHEMBL5227055 | 0.81 | PPARG (0.58) | PPARGPPARACYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778654-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | Crystalgenomics, Inc. (KR) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006006832-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | CRYSTALGENOMICS, INC. (KR) | 2006-01-19 | — | — | WO | disclosed |